Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis

Phase 3

Active, not recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Anti JAK1,2
Drug: Cyclophosphamid

First Posted Date: 2022-06-27

Last Posted Date: 2023-01-04

Lead Sponsor: Assiut University

Target Recruit Count: 60

Registration Number: NCT05432531

Locations: 🇪🇬
Manal Hassanien, Assiut, Assuit, Egypt

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

Phase 2

Recruiting

Conditions: DLBCL Germinal Center B-Cell Type

Interventions: Drug: Selinexor
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2022-06-16

Last Posted Date: 2024-06-17

Lead Sponsor: Li Zhiming

Target Recruit Count: 50

Registration Number: NCT05422066

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China

and more 3 locations

A Study for the Adjuvant Treatment of Breast Cancer

Phase 4

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Carboplatin
Drug: Epirubicin
Drug: Trastuzumab
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Pertuzumab
Drug: Nab paclitaxel

First Posted Date: 2022-06-15

Last Posted Date: 2022-07-01

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 2413

Registration Number: NCT05420467

Locations: 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

A Study for the Neoadjuvant Treatment of Breast Cancer

Phase 4

Recruiting

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: Epirubicin
Drug: Carboplatin
Drug: Trastuzumab
Drug: Cyclophosphamide
Drug: Pertuzumab
Drug: Nab paclitaxel

First Posted Date: 2022-06-15

Last Posted Date: 2022-07-01

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 1576

Registration Number: NCT05420454

Locations: 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Phase 1

Recruiting

Conditions: Recurrent High Grade B-Cell Lymphoma
Refractory B Acute Lymphoblastic Leukemia
Refractory Indolent Non-Hodgkin Lymphoma
Recurrent Acute Lymphoblastic Leukemia
Recurrent B-Cell Prolymphocytic Leukemia
Recurrent Non-Hodgkin Lymphoma
Recurrent Transformed Chronic Lymphocytic Leukemia
Refractory Non-Hodgkin Lymphoma
Recurrent B Acute Lymphoblastic Leukemia
Refractory High Grade B-Cell Lymphoma

Interventions: Biological: Anti-CD19/CD20/CD22 CAR T-Cells
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate

First Posted Date: 2022-06-14

Last Posted Date: 2024-05-17

Lead Sponsor: Sumithira Vasu

Target Recruit Count: 36

Registration Number: NCT05418088

Locations: 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Biological: Autologous MUC1-activated T-cells
Drug: Cyclophosphamide

First Posted Date: 2022-06-09

Last Posted Date: 2024-12-04

Lead Sponsor: Mayo Clinic

Target Recruit Count: 5

Registration Number: NCT05411497

Locations: 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

Phase 2

Active, not recruiting

Conditions: Lymphoma, Large B-Cell, Diffuse (DLBCL)

Interventions: Biological: Zilovertamab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin
Biological: Rituximab
Biological: Rituximab Biosimilar
Drug: Prednisone
Drug: Prednisolone

First Posted Date: 2022-06-06

Last Posted Date: 2024-10-14

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 60

Registration Number: NCT05406401

Locations: 🇰🇷
Seoul National University Hospital ( Site 0201), Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center ( Site 0200), Seoul, Korea, Republic of
🇨🇦
BC Cancer Victoria-Clinical Trials Unit ( Site 0105), Victoria, British Columbia, Canada

and more 19 locations

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Phase 1

Recruiting

Conditions: Colorectal Cancer
Hematologic Malignancy
Rectum Cancer
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Acute Lymphoblastic Leukemia
Chronic Myeloid Leukemia
Chronic Lymphocytic Leukemia
Hodgkin Lymphoma
Non Hodgkin Lymphoma

Interventions: Drug: Vactosertib
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Drug: IL-2
Drug: Natural Killer Cells

First Posted Date: 2022-06-01

Last Posted Date: 2024-11-29

Lead Sponsor: Jennifer Eva Selfridge, MD

Target Recruit Count: 12

Registration Number: NCT05400122

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas

Phase 1

Active, not recruiting

Conditions: Non Hodgkin Lymphoma

Interventions: Biological: UF-KURE19 CAR-T cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2022-06-01

Last Posted Date: 2024-06-06

Lead Sponsor: Changchun Deng, MD

Target Recruit Count: 10

Registration Number: NCT05400109

Locations: 🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1

Terminated

Conditions: Head and Neck Cancer
Ovarian Cancer
Pancreatic Cancer
Non Small Cell Lung Cancer
Colorectal Cancer
GastroEsophageal Cancer
Breast Cancer

Interventions: Drug: FT536
Drug: Cyclophosphamide
Drug: Fludarabine
Combination Product: Avelumab
Drug: IL-2
Combination Product: Pembrolizumab
Combination Product: Trastuzumab
Combination Product: Cetuximab
Combination Product: Amivantamab
Combination Product: Nivolumab
Combination Product: Atezolizumab

First Posted Date: 2022-05-27

Last Posted Date: 2023-09-21

Lead Sponsor: Fate Therapeutics

Target Recruit Count: 5

Registration Number: NCT05395052

Locations: 🇺🇸
Hackensack University Medical Center - John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸
UCLA Division of Hematology-Oncology, Los Angeles, California, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy